APA način citiranja

Johnson, M. L., Riely, G. J., Rizvi, N. A., Azzoli, C. G., Kris, M. G., Sima, C. S., . . . Miller, V. A. (2011). Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib.

Čikaški stil citiranja

Johnson, Melissa L., Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, i Vincent A. Miller. Phase II Trial of Dasatinib for Patients With Acquired Resistance to Treatment With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. 2011.

MLA način citiranja

Johnson, Melissa L., et al. Phase II Trial of Dasatinib for Patients With Acquired Resistance to Treatment With the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. 2011.